Bromantane

Bromantane is a Soviet-era compound originally developed for soldiers and cosmonauts, now used clinically in Russia (brand name Ladasten) for asthenia, a clinical condition of persistent fatigue with anxiety. It's the most famous example of an actoprotector, a class of drugs designed to make the body more resilient under stress without burning more energy or oxygen to do it. Most people outside Russia take it as a non-stimulant alternative to caffeine or amphetamines, for cognitive endurance, motivation, and a quiet lift in mood without the jittery edge.

Unlike a typical stimulant, bromantane doesn't dump dopamine into your system it upregulates tyrosine hydroxylase increasing dopamine synthesis capacity at the genetic level and also reduces anxiety through GABA modulation while improving cognition. if your main deficit is motivation, focus, and drive - this addresses the root cause by teaching your brain to produce more dopamine rather than just recycling what little you have.

It tells your neurons to make more of the machinery that produces dopamine, then steps back. Effects build gradually over a few days, plateau, and then linger for weeks after you stop. A typical course is 50-100 mg in the morning for 2-4 weeks, after which most people take a break. Outside Russia, it sits in the research-chemical gray market, with no regulatory approval and limited long-term human safety data beyond about 8 weeks.

Deep-dive

Bromantane is an adamantane derivative, structurally related to amantadine and memantine. It was developed at the Soviet Military Medical Academy in the 1980s, picked up notoriety in 1996 when five athletes tested positive for it at the Atlanta Olympics, and was approved in Russia for asthenia in 1997, then re-registered as Ladasten for neurasthenia around 2009. Outside Russia it has no approved medical indication.

The actoprotector concept. Actoprotectors are a class of compounds that increase resistance to physical and mental stress without raising oxygen consumption or heat production. That's the line that separates them from classical stimulants. Amphetamine makes you push harder while burning hotter; bromantane makes the system more efficient at the load it's already under. The PMC review of actoprotector pharmacology is the cleanest English-language summary of this body of work.

Mechanism. This is the part that makes bromantane interesting. Whereas amphetamines and methylphenidate work by blocking dopamine reuptake or forcing release, bromantane acts indirectly through gene expression. Research summarised on its mechanism page shows it upregulates two key enzymes in dopamine biosynthesis: tyrosine hydroxylase (TH, the rate-limiting enzyme) and aromatic L-amino acid decarboxylase (AAAD). A single dose produces a 2-2.5 fold increase in TH expression in the rat hypothalamus within 1.5-2 hours. More enzyme means more dopamine is built from tyrosine over time, in the regions that need it (hypothalamus, striatum, ventral tegmental area, nucleus accumbens). It also strengthens GABAergic inhibition and modestly affects serotonin, which is probably why the subjective experience is closer to calm-focus than wired stimulation.

Pharmacokinetics. Oral bioavailability is around 42%. Peak plasma is reached at roughly 4 hours in men and 2.75 hours in women, a genuine and well-documented sex difference. The elimination half-life is around 11 hours in humans, but bromantane is highly lipophilic and accumulates in adipose and brain tissue, so metabolites can be detected in urine for up to two weeks after a single dose. The main metabolite is 6β-hydroxybromantane. Steady-state takes about a week of daily dosing, which lines up with what users report subjectively.

Asthenia, the headline trial. Most of the human data sits inside one large multicenter Russian study. In 728 patients with asthenic disorders, 50-100 mg daily for 28 days produced a 76% responder rate on the CGI-S and 90.8% on the CGI-I. Effects appeared by day 3 and persisted one month after stopping. Side effects occurred in 3% of patients and were mild; only 0.8% discontinued. A randomised placebo-controlled trial in neurasthenia confirmed superiority over placebo with no withdrawal syndrome on stopping. The persistence of benefit after discontinuation is consistent with the genomic mechanism: enzyme density doesn't drop the moment the drug clears.

Cognition in healthy people. A small EEG study in 10 healthy volunteers given a single oral dose found bromantane produced an increase in mid-frequency alpha-rhythm power and reduced delta and beta1 power, an EEG signature similar to mild stimulants with antiamnestic and antihypoxic properties. It didn't change subjective state in rested volunteers, but it improved vigilance markers and reduced tremor, which fits the broader pattern: bromantane shows up most when the system is under load.

Inflammation and depression. In animal models of depression, bromantane lowered IL-6, IL-17, and IL-4 and reversed depressive behaviours, in a pattern comparable to imipramine. Inflammatory cytokines like IL-6 are now well-established contributors to depressive symptoms, so this is a plausible second pathway alongside the dopaminergic one. Human antidepressant data is limited to the asthenia trials, where mood and anxiety scores improved alongside fatigue.

Sexual function. Through dopaminergic action, bromantane appears to suppress prolactin (high prolactin lowers libido and dampens the HPG axis). A rat study found 3-day treatment increased sexual proceptivity dose-dependently, and chronic treatment increased both proceptivity and receptivity in both sexes. In stressed male rats, bromantane restored normal spermatogenesis and reduced embryo loss. Human data is anecdotal, but improved libido is a common user report.

Women. Most of the published clinical data, including the 728-patient asthenia trial, included both men and women, with no sex-specific safety signals. Two practical differences stand out. First, women absorb bromantane faster and reach peak plasma earlier (2.75 vs 4 hours), so onset is quicker. Second, oestrogen upregulates dopamine synthesis on its own, so women in the high-oestrogen phase of the cycle may already be running closer to ceiling and notice less added effect, while women in the low-oestrogen phase (late luteal, perimenopause, postmenopause) often report a more obvious lift. The receptivity findings in female rats and the prolactin-lowering mechanism are reasons some women find it useful for libido, particularly where prolactin is elevated. Skip it in pregnancy and breastfeeding. Animal studies in lactating rats show bromantane can suppress prolactin enough to affect milk production and offspring development.

What the evidence does not yet show. Almost all the human data is Russian, much of it open-label, and the longest controlled trials run 28 days. There is no Western replication of the large asthenia trial, no head-to-head comparison against modafinil, methylphenidate, or SSRIs, and no long-term (1+ year) safety data. Subjective reports outside the clinical setting vary widely, from "steady, clean energy" to "nothing at all" to "emotionally blunted at higher doses." The drug works best as a short course in someone who is genuinely depleted, not as a daily tonic in someone already running fine.

Dosage:

Standard dose: 50-100 mg once daily, taken in the morning. Most people start at 50 mg for the first few days and step up to 100 mg if tolerated. This is the dose used in essentially all of the published clinical work

Course length: Typical courses are 2-4 weeks. The 728-patient trial used 28 days, which is the longest well-documented exposure in a controlled setting. Effects often persist 2-4 weeks after stopping, so cycling rather than continuous use makes sense

Onset and timing: Effects build gradually. You may notice something on day 1-3, but the fuller lift in motivation and mood typically lands by day 7-10. Always take in the morning. The half-life is around 11 hours and tissue accumulation extends action further; afternoon dosing is the most common cause of insomnia. Women reach peak plasma faster than men (2.75 vs 4 hours), so onset on dosing days is slightly quicker for women

With or without food: Doesn't matter much for absorption. Some users find taking it with food reduces mild GI discomfort

Higher doses: Self-experimentation above 100 mg/day rarely adds benefit and often produces irritability, headache, or a flat, emotionally blunted feeling. Bromantane has an inverted-U curve. More is not better

Stacking: Pairs reasonably with caffeine, since they hit different systems (caffeine blocks adenosine, bromantane builds dopamine machinery). Avoid stacking with high-dose stimulant ADHD medications, MAOIs, or other strongly dopaminergic drugs. Bromantane induces hepatic CYP-450 enzymes, which can shorten the duration of benzodiazepines, hormonal contraceptives, SSRIs, and other CYP-metabolised drugs over a course

Cycling: A common pattern is 4 weeks on, 4-8 weeks off. Because effects linger after stopping, this lets you assess whether you actually need another course or whether the underlying state has reset

Here's what you can expect:

In the right context (chronic fatigue, low motivation, post-illness asthenia, burnout, sleep-deprived stretches, training under heat or stress), most people notice a quiet, steady lift over the first 1-2 weeks. Effects build over 3-7 days and persist weeks after stopping because you've changed gene expression. Mental endurance improves before subjective energy does. Anxiety eases without sedation. Sleep tends to normalise rather than worsen, provided you're dosing in the morning. Libido often picks up. The effect is more like a baseline reset than a stimulant hit, you should feel like a slightly more capable version of yourself, not amped or chemically altered.

In the wrong context (rested, well-fed, no significant stressor, looking for something to feel), most people report nothing or only mild alerting. Bromantane needs something to push back against. People with normal-to-high baseline dopamine tone often get the least from it.

A few people report the opposite, irritability, edginess, or a flat "cold focus" where empathy and warmth dim. This usually means the dose is too high or the course has run too long. Cutting to 50 mg or stopping resolves it.

Unlike caffeine or amphetamines, you should not feel a clear daily pulse from each dose. The benefit accrues over days. If you're chasing an acute kick, you'll be disappointed and may push the dose too high.

Side effects & risks:

Insomnia is by far the most common complaint, almost always traceable to late dosing. The half-life and tissue accumulation mean an afternoon dose can keep you wired into the early hours. Stick to morning use

Irritability, restlessness, or tension headaches at doses above 100 mg or with chronic daily use beyond 4 weeks. Resolves with dose reduction or a break

Mild GI discomfort (nausea, loose stools) in some users, particularly at higher doses or on an empty stomach

Emotional blunting at higher doses or on extended courses, sometimes described as a flat, analytical "cold focus." A signal to step down

CYP-450 induction: Bromantane induces liver enzymes including cytochrome P-450. Animal data show it cuts thiopental sleep time by roughly a third. In practical terms, expect potentially reduced effect of CYP-metabolised drugs taken alongside it (some benzodiazepines, hormonal contraceptives, certain SSRIs, statins, warfarin). If you rely on hormonal contraception, a course of bromantane is a non-trivial concern; talk to your clinician or use backup methods

MAOI interaction: Combining bromantane with monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline) is a hard contraindication. The dopaminergic load combined with impaired clearance can produce hypertensive crisis

Stimulant stacking: Avoid combining with high-dose amphetamines or methylphenidate. Bromantane has been shown to potentiate amphetamine-induced behavioural effects in animals

Cardiovascular profile is favourable at clinical doses (50-100 mg). Unlike amphetamines, bromantane does not consistently raise heart rate or blood pressure, but caution applies if you're already on compounds that push BP up

Pregnancy and breastfeeding: Avoid. Animal studies show suppression of prolactin and possible effects on offspring development at higher doses; there is no human safety data

Long-term unknowns: Human controlled data essentially ends at 28 days. Effects on liver enzymes over months, hormonal changes (prolactin, thyroid, HPG axis), and cognitive impact of repeated long courses have not been studied in any rigorous way outside Russia

Sourcing: Outside Russia, bromantane is sold as a research chemical with no regulatory oversight. Independent testing has occasionally found underdosed or contaminated product. If you're using it, third-party tested sources matter

Sport: Banned by WADA. If you're a tested athlete, do not use it. Metabolites are detectable for weeks after a single dose

🩸

Blood markers

Liver enzymes (ALT, AST, GGT), baseline before starting and at the end of a 4-week course. Bromantane induces hepatic CYP-450 enzymes; while clinical hepatotoxicity has not been reported, monitoring makes sense if you run repeated courses or stack other liver-metabolised compounds.

Prolactin, baseline if libido or mood is the main reason you're taking it, and again at 4 weeks. Bromantane suppresses prolactin via dopaminergic action, and a meaningful drop tracks with subjective improvement in libido and motivation.

TSH, free T4, free T3, baseline if you're using it for chronic fatigue. Subclinical hypothyroidism mimics asthenia and is missed often. If your TSH is high, treat the thyroid first.

CBC and basic metabolic panel, baseline if you're stacking with other compounds or running multiple courses per year.

For most people running a single 2-4 week course at 50-100 mg in an otherwise stable state, no specific bloodwork is required.

Sold in Russia by prescription as Ladasten. Outside Russia it's unscheduled in most jurisdictions but unapproved for human use, and is banned in competitive sport by WADA.